GlassScriptPhysician profile
Michael J Collins
NPI 1801882394
$9,911.27
in general payments reported to CMS, 2019-2025
17 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $154 · 2021: $2,050 · 2022: $1,000 · 2023: $602 · 2024: $4,453 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395 · Consulting Fee: $2,800 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,394.67 |
| Consulting Fee | $2,800.00 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $3,455.19 | 2022-2025 | Victus, Envista Envy Iol, Stellaris |
| Sight Sciences, INC. | $2,375.45 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,005.31 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $579.33 | 2019-2025 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Rxsight INC | $376.74 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $292.86 | 2021-2025 | Dextenza |
| Alcon Vision LLC | $225.80 | 2019-2025 | Clareon |
| Biotissue Holdings INC. | $207.43 | 2024-2025 | |
| Glaukos Corporation | $164.20 | 2019-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $101.99 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $29.31 | 2024 | Eylea Hd, Eylea |
| Oyster Point Pharma, INC. | $21.38 | 2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $17.32 | 2021 | |
| Rayner Intraocular Lenses Limited | $16.43 | 2025 | Omidria |
| Eyevance Pharmaceuticals LLC | $15.87 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $15.29 | 2020 | |
| Allergan, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.